Everything below concerns WADA Prohibited List. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-04-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human therapeutic use | No marketing authorization identified in major jurisdictions. |
| Anti-doping class | PPARδ agonist; hormone and metabolic modulators | Listed on the WADA Prohibited List. |
| Common test matrix | Urine | Also blood and tissue in research settings. |
| Typical analytical method | LC-MS/MS | Targets parent compound and metabolites. |
| Major safety signal | Tumor findings in rodents | Human relevance not established; limited human data. |
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
== Systemic effects == An infectious organism can escape the confines of the immediate tissue via the circulatory system or lymphatic system, where it may spread to other parts of the body. If an organism is not contained by the actions of acute inflammation, it may gain access to the lymphatic system via nearby lymph vessels. An infection of the lymph vessels is known as lymphangitis, and infection of a lymph node is known as lymphadenitis. When lymph nodes cannot destroy all pathogens, the infection spreads further. A pathogen can gain access to the bloodstream through lymphatic drainage into the circulatory system. When inflammation overwhelms the host, systemic inflammatory response syndrome is diagnosed. When it is due to infection, the term sepsis is applied, with the terms bacteremia being applied specifically for bacterial sepsis and viremia specifically to viral sepsis. Vasodilation and organ dysfunction are serious problems associated with widespread infection that may lead to septic shock and death.
=== Indirect TPMS === Indirect TPMS (iTPMS) systems do not use physical pressure sensors; they measure air pressures using software-based systems, which by evaluating and combining existing sensor signals such as wheel speeds, accelerometers, and driveline data to estimate and monitor the tire pressure without physical pressure sensors in the wheels. First-generation iTPMS systems are based on the principle that under-inflated tires have a slightly smaller diameter (and hence higher angular velocity) than a correctly inflated one. These differences are measurable through the wheel speed sensors of ABS/ESC systems. Second generation iTPMS can also detect simultaneous under-inflation in up to all four tires using spectrum analysis of individual wheels, which can be realized in software using advanced signal processing techniques. iTPMS systems are sometimes referred to by other names, such as Ford's ‘Deflation Detection System (DDS)’ or Honda's ‘Deflation Warning System (DWS)’. iTPMS cannot measure or display absolute pressure values; they are relative by nature and have to be reset by the driver once the tires are checked and all pressures adjusted correctly. The reset is normally done either by a physical button or in a menu of the on-board computer. iTPMS are, compared to dTPMS, more sensitive to the influences of different tires and external influences like road surfaces and driving speed or style.
=== Persistent infection === Most often, SeV infection initiates an apoptotic program in the host cells, which leads to the death of target cells without interrupting the life cycle of the virus. However, paramyxoviruses, including SeV, can cause persistent infection in primary cell cultures that does not kill cells or turn off cellular RNA transcription and translation. It has been demonstrated that mouse connective tissues cells (L-929) and hamster kidney fibroblasts (BHK-21) can become infected with Sendai virus and the infection can be persistent. The possibility of establishing a persistent viral infection was demonstrated in SeV-infected ovine fibroblasts.
Becoming a pathologist generally requires specialty-training after medical school, but individual nations vary somewhat in the medical licensing required of pathologists. In the United States, pathologists are physicians (D.O. or M.D.) who have completed a four-year undergraduate program, four years of medical school training, and three to four years of postgraduate training in the form of a pathology residency. Training may be within two primary specialties, as recognized by the American Board of Pathology: anatomical pathology and clinical pathology, each of which requires separate board certification. The American Osteopathic Board of Pathology also recognizes four primary specialties: anatomic pathology, dermatopathology, forensic pathology, and laboratory medicine. Pathologists may pursue specialised fellowship training within one or more subspecialties of either anatomical or clinical pathology. Some of these subspecialties permit additional board certification, while others do not. In the United Kingdom, pathologists are physicians licensed by the UK General Medical Council. The training to become a pathologist is overseen by the Royal College of Pathologists. After four to six years of undergraduate medical study, trainees proceed to a two-year foundation program. Full-time training in histopathology currently lasts between five and five and a half years, encompassing specialist training in surgical pathology, cytopathology, and autopsy pathology.
The connecting peptide, or C-peptide, is a short 31-amino-acid polypeptide that connects insulin's A-chain to its B-chain in the proinsulin molecule. In the context of diabetes or hypoglycemia, a measurement of C-peptide blood serum levels can be used to distinguish between different conditions with similar clinical features. In the insulin synthesis pathway, first preproinsulin is translocated into the endoplasmic reticulum of beta cells of the pancreas as one polypeptide comprising the regions of the A-chain, C-peptide, B-chain, and signal sequence. The signal sequence is cleaved from the N-terminus of the peptide by a signal peptidase, leaving proinsulin. After proinsulin is packaged into vesicles in the Golgi apparatus (beta-granules), the C-peptide is removed, leaving the A-chain and B-chain bound together by disulfide bonds, that constitute the insulin molecule. C-peptide has virtually no affinity for the insulin receptor, however, it is known to promote the activity of at least two enzymes - the sodium–potassium pump and nitric oxide synthase - downstream of binding to a membrane structure (presumably a G protein-coupled receptor). Nevertheless, the physiological significance of these effects of C-peptide is unresolved.
Sources: en.wikipedia.org
An etorphine antidote Large Animal Revivon contains mainly diprenorphine for animals and a human-specific naloxone-based antidote, which should be prepared prior to the etorphine. A 5–15 mg dose is enough to immobilise an African elephant and a 2–4 mg dose is enough to immobilise a black rhinoceros.
Some of the earliest human remains found in the Americas, Luzia Woman, were found in the area of Pedro Leopoldo, Minas Gerais, and provide evidence of human habitation going back at least 11,000 years. The earliest pottery ever found in the Western Hemisphere was excavated in the Amazon basin of Brazil and radiocarbon dated to over 8,000 years ago (6000 BC). The pottery was found near Santarém and provides evidence that the region supported a complex prehistoric culture. The Marajoara culture flourished on Marajó in the Amazon delta from AD 400 to 1400, developing sophisticated pottery, social stratification, large populations, mound building, and complex social formations such as chiefdoms. Around the time of the Portuguese arrival, the territory of present day Brazil had an estimated Indigenous population of 7 million people, mostly semi-nomadic, who subsisted on hunting, fishing, gathering, and migrant agriculture. The population comprised several large Indigenous ethnic groups (e.g., the Tupis, Guaranis, and Gês. The Tupi people were subdivided into the Tupiniquins and Tupinambás. Before the arrival of the Europeans, the boundaries between these groups and their subgroups were marked by wars that arose from differences in culture, language and moral beliefs. These wars also involved large-scale military actions on land and water, with cannibalistic rituals on prisoners of war. While heredity had some weight, leadership was a status more won over time than assigned in succession ceremonies and conventions.
Cilofexor (also known as GS-9674) is a nonsteroidal farnesoid X receptor (FXR) agonist in clinical trials for the treatment of non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and primary sclerosing cholangitis (PSC). It is being investigated for use alone or in combination with firsocostat, selonsertib, or semaglutide. In rat models and human clinical trials of NASH it has been shown to reduce fibrosis and steatosis, and in human clinical trials of PSC it improved cholestasis and reduced markers of liver injury. It is being developed by the pharmaceutical company Gilead Sciences.
Biochemically, individuals with ALD show very high levels of unbranched, saturated, very long chain fatty acids, particularly cerotic acid (26:0). The level of cerotic acid in plasma does not correlate with clinical presentation. Treatment options for ALD are limited. For the childhood cerebral form, stem cell transplant and gene therapy are options if the disease is detected early in the clinical course. Adrenal insufficiency in ALD patients can be successfully treated. ALD is the most common peroxisomal inborn error of metabolism, with a minimum estimated incidence of 1:42,000 for hemizygotes and 1:16,800 for hemizygotes and heterozygotes, though the incidence is likely to increase with improved newborn screening. It does not have a significantly higher incidence in any specific ethnic group.
== Health economics == Economic analyses suggest that TOPS may be cost-effective compared with fusion. These findings are based on improvements in quality of life, faster recovery, and reduced need for reoperation over time.
Sources: en.wikipedia.org
{\displaystyle h{{\left[{\frac {\mu _{v}^{2}}{g{{\rho }_{v}}\left({{\rho }_{L}}-{{\rho }_{v}}\right)k_{v}^{3}}}\right]}^{{}^{1}\!\!\diagup \!\!{}_{3}\;}}=0.0020{{\left[{\frac {4m}{\pi {{D}_{v}}{{\mu }_{v}}}}\right]}^{0.6}}}
=== Legal status === In January 2016, Eli Lilly submitted a new drug application to the US Food and Drug Administration (FDA) for the approval of baricitinib to treat moderately-to-severely active rheumatoid arthritis. In December 2016, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended the approval of baricitinib as a therapy for rheumatoid arthritis. European Union approval was granted in February 2017. Despite widespread expectations that the FDA would approve baricitinib for rheumatoid arthritis, in April 2017, the FDA issued a rejection, citing concerns about dosing and safety. In May 2018, baricitinib was approved in the United States for the treatment of rheumatoid arthritis. In March 2020, the US FDA granted breakthrough therapy designation to baricitinib for the treatment of alopecia areata and granted approval in June 2022. The efficacy and safety of baricitinib in alopecia areata was studied in two randomized, double-blind, placebo-controlled trials (Trial AA-1 and Trial AA-2) with participants who had at least 50% scalp hair loss as measured by the Severity of Alopecia Tool (SALT) for more than six months. Participants in these trials received either a placebo, 2 milligrams of baricitinib, or 4 milligrams of baricitinib every day. The primary measurement of efficacy for both trials was the proportion of participants who achieved at least 80% scalp hair coverage at week 36.
=== Silk fibroin === Silk fibroin is the load-bearing protein of silkworm silk and the basis of most silk biomaterials. In Bombyx mori it consists of a large heavy chain of about 390 kilodaltons linked by a disulfide bond to a much smaller light chain of about 26 kilodaltons, together with a small glycoprotein. The heavy chain is dominated by long, repetitive runs of three small amino acids: glycine, alanine and serine. These sequences fold into tightly packed, ordered domains known as beta sheets, stabilised by extensive hydrogen bonding and separated by less ordered regions. This arrangement gives silk its unusual combination of stiffness and toughness. Much of a silk material's behaviour depends on these beta-sheet domains—their abundance and their degree of alignment. Solid silk exists in two principal forms: a less stable form, sometimes designated Silk I, and the more stable, crystalline beta-sheet form, Silk II. Most processing is concerned with controlling the conversion between the two, since a higher beta-sheet content produces a material that is stronger, less soluble in water and slower to degrade.
== Revisionism == The role of the United States in the Vietnam War disillusioned New Left historians and created many historians with sympathy towards the Viet Cong communist position and antipathy towards American policies. Much more important were the revisionists who argued that both United States and the Soviet Union were responsible for blundering into the war and rejected the premises of "containment". They battled the "orthodox" historians. "Revisionist" accounts emerged in the wake of the Vietnam War in the context of a larger rethinking of the United States role in international affairs, which was seen more in terms of American empire or hegemony. In the specific context of the Vietnam War, this "revisionist" narrative became the historiographical orthodoxy, whereas revisionism in Vietnam War historiography came to defend the US policy of containment. While the new school of thought spanned many differences among individual scholars, the works comprising it were generally responses in one way or another to William Appleman Williams 1959 volume, The Tragedy of American Diplomacy. Williams challenged the long-held assumptions of "orthodox" accounts, arguing that Americans had always been an empire-building people even while American leaders denied it. The influence of Williams, who taught at the University of Wisconsin–Madison, and several of his students who subsequently published works on these themes, was enough to create what became known as the Wisconsin School of American diplomatic history.
==== Drugs with unknown mechanisms of action ==== Amantadine (Symmetrel) – unknown mechanism of action and ionotropic glutamate NMDA receptor antagonist (indirect dopaminergic agent) Amantadine extended release (ADS-5101; ADS-5102; Gocovri; Nurelin) – unknown mechanism of action and ionotropic glutamate NMDA receptor antagonist (indirect dopaminergic agent) – drug-induced dyskinesia in Parkinson's disease [343] Budipine (BY-701; Parkinsan) – unknown mechanism of action and ionotropic glutamate NMDA receptor antagonist [344]
Sources: en.wikipedia.org
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.
It is classified as a PPARδ agonist on the WADA Prohibited List. Anti-doping laboratories can detect it and its metabolites in urine. Its use is banned in competition and usually out of competition.
Rodent studies reported increased tumor incidence at multiple sites. The human relevance remains uncertain, but the findings contributed to discontinuation of development. No long-term human cancer data are available.
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.